Report Value-Based Healthcare

The Implications for Pharma Strategy


Get the Report

Value-Based Healthcare summary
Dramatic changes in the world of health care hold special implications for Big Pharma.


7 Overall

8 Importance

8 Innovation

6 Style


The system of how medical care providers get reimbursed has undergone – and is continuing to undergo – tremendous change. Under the umbrella of “value-based health care” (VBH), the quality of patients’ case results determines the payments to medical providers and health care suppliers – rather than the quantity of tests, procedures or medications a patient receives. Experts at the Economist Intelligence Unit succinctly describe how these changes will affect the big pharmaceutical companies that create and market medications to millions of people. Their report offers compelling examples of how these firms can cope with and benefit from VBH. getAbstract recommends this illuminating report on the shake-up in health care to pharma professionals, health care providers and suppliers, as well as entrepreneurs and investors in the medical arena.

In this summary, you will learn

  • What “value-based health care” is,
  • What challenges it poses to pharmaceutical companies and
  • How pharma can adapt to those changes.


The New World
Changes in the health care industry radically affect “health care funding” – the basis on which reimbursers pay medical and drug costs. Under “value-based health care” (VBH), “patient outcomes” are the standard for payment. Industry experts see value-based health care as ...
Login or Register

About the Author

The Economist Intelligence Unit Healthcare provides information to aid health care providers, suppliers, payers and others in developing research- and evidence-based business plans.

Comment on this summary

More on this topic

By the same author

Customers who read this summary also read

More by category